Developing a Controlled Human Infection Model for Group B Streptococcus (CHIM_GBS)
NCT ID: NCT04059510
Last Updated: 2020-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2019-11-04
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The current strategy to prevent neonatal GBS is to give antibiotics during labour, called IAP. This has various limitations and is not easily achieved outside of high income settings. Additionally, widespread antibiotic use raises concerns about antibiotic resistance. A better approach would be a vaccine for GBS however in order to test any vaccines it would be necessary to develop a controlled human infection model whereby healthy female volunteers are artificially colonised with GBS to test the vaccines efficacy. Before developing these human infection models researchers need to better understand how women become colonised with GBS and whether antibodies in the blood and at the mucosal surfaces provide protection. This study will be observational and will test the antibody levels at the vaginal mucosa and in the blood of a group of women who are naturally colonised with GBS at the start of the study and a group who are not colonised. Investigators will follow women up over 12 weeks to observe how colonisation changes and the effect that this has on the mucosal and blood stream antibody concentrations. This will inform the development of human infection studies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection
NCT02471937
Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis
NCT01719510
Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study
NCT00920530
The Clinical and Molecular Epidemiology of Streptococcus Agalactiae Colonisation on the Kenyan Coast
NCT01757041
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
NCT01982084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Maternal rectovaginal colonization with GBS is a prerequisite for early onset disease within the first 6 days of life, with vertical GBS transmission occurring around the time of birth2. An estimated 20-35% of pregnant women are colonised with GBS with vertical transmission occurring in approximately 50% of colonized cases3. 1-2% of neonates born to GBS-colonised women develop invasive disease in the absence of intrapartum antibiotic prophylaxis (IAP)4.
Whilst the incidence of Early Onset Disease in the USA has declined significantly following the adoption of a universal swab-based screening and IAP policy, in countries adopting a risk-based IAP strategy, such as the UK, increases in Early Onset disease burden are reported.4. IAP has limitations as a strategy for use in countries such as Uganda due to cost and access to healthcare, as well as the risk of antimicrobial resistance developing.
Given the early onset of neonatal GBS disease and the shortcomings of IAP policies, one of the best approaches to prevent GBS disease could be to use vaccination to prevent colonisation of pregnant women. The ideal model to test any GBS vaccine would be a controlled human infection model in non-pregnant women, however in order to develop this controlled human infection model researchers need to understand how host immunity affects GBS colonisation. Around 25-30% of non-pregnant women are colonised with GBS at any time and colonisation may be lost or gained over a lifetime. Prior to performing controlled human infection models, researchers need to further understand the correlation between colonisation and GBS antibody production in serum and at mucosal surfaces and researchers need to better understand how colonisation changes over time in healthy, non-pregnant women and given the observed differences in GBS disease in high and low income countries it would be useful to perform these observations in different geographical locations.
RATIONALE
Firstly, investigators need to determine levels of pre-existing local and systemic immunity in GBS colonised and uncolonised women that could be used as inclusion/exclusion criteria in a controlled human infection model, and to achieve this investigators need to optimise sampling techniques.
Secondly, investigators need to understand differences in vaginal immunity that may be due to genetic or geographical differences in order to demonstrate the potential for global applicability of any potential vaccine candidate this is the rationale for conducting the study in the UK and Uganda. Finally investigators need to clarify who could (and would) be likely to volunteer to take part in controlled human infection model studies for GBS.
THEORETICAL FRAMEWORK
Correlation between vaginal sero-specific Immunoglobulin G to GBS has been found in pregnant women with less colonisation in those women with higher levels of Immunoglobulin G suggesting a level of natural immunity5. It is unclear how long Immunoglobulin G in blood remains high following colonisation and whether this decreases over time leading to increased future susceptibility. There is little published research on how GBS colonisation naturally changes over time and whether this correlates with vaginal and serum serotype-specific GBS Immunoglobulin G levels.
In order to develop a human infection model, it would be useful to know how natural colonisation varies over time and its relationship with natural immunity, such that for future vaccine studies researchers would know whether observed non-colonisation is due to vaccine or natural immunity.
A secondary aim is to explore whether human infection models of GBS would be acceptable to women given the complex nature of GBS colonisation and its potential impact on subsequent pregnancies.
This will be a prospective cohort study of 100 women (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site sampled over 12 weeks to assess antibodies in the vagina every two weeks and in blood every 6 weeks. The study will also include a focus group to understand acceptability of methods for the proposed human infection challenge model of GBS.
1. Screening for GBS Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic Sexually transmitted infections screen according to local usual practice. In both the UK and Uganda this screening will look for Chlamydia, Gonorrhoea, Trichomonas vaginalis, Bacterial Vaginosis, Candida and for Syphilis, HIV and Hepatitis B and C. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection. Of the 250 women screened, the investigators will aim to recruit 50 women who are positive for GBS and 50 negative for GBS to take part in the sampling study. Consent to undertake the screening will be done initially with a further consent process for the sampling study.
Screening will involve three self-taken vaginal swabs and a rectal swab for GBS detection and Sexually transmitted infections detection and a venous blood sample for HIV, syphilis and Hepatitis B and C. A brief medical history will be conducted at screening to exclude women with a history of diabetes, genital dermatoses, Cervical Intra-epithelial Neoplasia or other condition which the investigator deems may make them unsuitable to take part in the sampling study. A bedside urine pregnancy test will be performed at screening. HIV and Hepatitis B and C are not exclusion criteria however this information is needed in the analyses as there is a possibility that women with HIV in particular do not have the same antibody response to colonisation.
2. Sampling method optimisation If a woman is deemed to meet all inclusion criteria and no exclusion criteria at screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent for participation in a focus group at the end of the study. Consent to participate in the focus group will be optional.
The sampling study will last for 12 weeks and samples will be collected as follows:
1. A self-taken low vaginal swab using swabs at enrolment and then two weekly intervals, (Day 0, day 14, day 28, Day 42, day 56, day 70 and day 84) for GBS carriage.
2. A self-taken rectal swab at recruitment and then at two weekly intervals (Day 0, day 14, day 28, Day 42, day 56, day 70 and day 84.) which will be tested for GBS carriage.
3. Menstrual cup fluid at recruitment and then at two weekly intervals (Day 0, day 14, day 28, Day 42, day 56, day 70 and day 84) which is tested for Immunoglobulin G antibody (total and GBS specific).
4. Serum sample at day 0 and at day 42 and day 84 for Immunoglobulin G detection (total and GBS specific) - 10 mls of blood will be collected using sterile needle and syringe into serum separator tubes.
5. Urine pregnancy tests will be performed at day 0, day 42 and day 84 to ensure no pregnancies during the study.
Women may choose whether to self-sample with rectovaginal swabs and menstrual cups at home or on attendance for their study visit. Blood tests and urine pregnancy tests will always be performed by the study team.
3. Focus groups In the UK the investigator will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional. Women may opt out of the focus groups at any time but remain in the sampling study if they choose.
In Uganda, the investigators will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders. Investigators will directly contact potential focus group participants. Focus groups will be conducted on the acceptability of controlled human infection models. Investigators will also explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples. From the Ugandan focus groups the investigator will ask 30 volunteers (10 men and/or community leaders, 10 women and 10 midwives) to participate in three further discussion groups to explore more in-depth views about the safety and acceptability of vaginal swabs and menstrual cups, potential hesitancy in consenting to have samples taken and potential barriers to joining the study.
Results from the focus groups will be used to inform patient information leaflets and sampling protocol for the design of a controlled human infection model study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening for GBS
Women will be recruited for screening for GBS in the UK and Uganda (250 at each site). At screening women will be consented for a vaginal and rectal swab to assess for GBS carriage and will also undergo an asymptomatic STI screen according to local usual practice. Anyone who meets the full inclusion criteria following screening will be invited to take part in the sampling study until the recruitment targets are reached. If any woman tests positive for any of the infections, she will be referred to a local centre for treatment and may still be included after completed treatment for the infection.
rectovaginal swab
Self taken rectal and vaginal swab
pregnancy test
Urine pregnancy test
Blood test
Venous blood sample
Sampling method optimisation
If a woman is deemed to meet all inclusion criteria and no exclusion criteria following screening and is willing to take part in the sampling method optimisation study, she will be consented again for the further study including consent (optional) for participation in a focus group at the end of the study. 100 eligible women will be recruited on to this part of the study (50 colonised with GBS at baseline and 50 uncolonised with GBS at baseline) at each site (UK and Uganda).
The sampling study will last for 12 weeks and samples collected include:
* A self-taken low vaginal swab
* A self-taken rectal swab
* Menstrual cup fluid
* Serum sample
* Urine pregnancy tests
rectovaginal swab
Self taken rectal and vaginal swab
pregnancy test
Urine pregnancy test
Menstrual cup
Menstrual cup vaginal fluid collection
Blood test
Venous blood sample
Focus groups
In the UK investigators will recruit up to 20 women from the sampling study to take part in focus groups about their experiences with self-sampling methods and the acceptability of controlled human infection models. Consent to participate in focus group discussions will be included as part of the consent to take part in the sampling study but will be optional.
Women may opt out of the focus groups at any time but remain in the sampling study if they choose.
In Uganda, the investigator will recruit more widely to our focus groups, including representation from midwives and the participant's partners and community leaders.The investigator will explore potential issues around maternal vaccination, and traditional and contemporary views on taking vaginal swabs and blood samples.
Focus group
Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rectovaginal swab
Self taken rectal and vaginal swab
pregnancy test
Urine pregnancy test
Menstrual cup
Menstrual cup vaginal fluid collection
Blood test
Venous blood sample
Focus group
Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy
* Willing to comply with study protocol requirements
* Able to give informed consent
* Willing not to become pregnant and use adequate contraception for length of study
Exclusion Criteria
* Intra-Uterine Device/Intra-Uterine System
* Presence of untreated sexually transmitted infections at baseline
* Known Diabetes
* Genital dermatoses
* Diagnosis of Cervical Intraepithelial Neoplasia within past 3 years
* Current pregnancy
* Post-Menopausal
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St George's, University of London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Cosgrove, PhD,MRCP
Role: PRINCIPAL_INVESTIGATOR
St Georges University Hospital NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St George's, University of London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Catherine Isitt, Dr
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Blencowe H, Cousens S, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag SJ, Sobanjo-Ter Meulen A, Vekemans J, Lawn JE. Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children. Clin Infect Dis. 2017 Nov 6;65(suppl_2):S200-S219. doi: 10.1093/cid/cix664.
Le Doare K, Heath PT, Plumb J, Owen NA, Brocklehurst P, Chappell LC. Uncertainties in Screening and Prevention of Group B Streptococcus Disease. Clin Infect Dis. 2019 Aug 1;69(4):720-725. doi: 10.1093/cid/ciy1069.
Le Doare K, Kampmann B, Vekemans J, Heath PT, Goldblatt D, Nahm MH, Baker C, Edwards MS, Kwatra G, Andrews N, Madhi SA, Ter Meulen AS, Anderson AS, Corsaro B, Fischer P, Gorringe A. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019 May;19(5):e162-e171. doi: 10.1016/S1473-3099(18)30659-5. Epub 2019 Jan 22.
Le Doare K, Faal A, Jaiteh M, Sarfo F, Taylor S, Warburton F, Humphries H, Birt J, Jarju S, Darboe S, Clarke E, Antonio M, Foster-Nyarko E, Heath PT, Gorringe A, Kampmann B. Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort. Vaccine. 2017 May 19;35(22):2970-2978. doi: 10.1016/j.vaccine.2017.04.013. Epub 2017 Apr 24.
Russell NJ, Seale AC, O'Driscoll M, O'Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Le Doare K, Madhi SA, Rubens CE, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Saha SK, Ip M; GBS Maternal Colonization Investigator Group. Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses. Clin Infect Dis. 2017 Nov 6;65(suppl_2):S100-S111. doi: 10.1093/cid/cix658.
Le Doare K, O'Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, Heath PT, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Kampmann B; GBS Intrapartum Antibiotic Investigator Group. Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review. Clin Infect Dis. 2017 Nov 6;65(suppl_2):S143-S151. doi: 10.1093/cid/cix654.
Haeusler IL, Daniel O, Isitt C, Watts R, Cantrell L, Feng S, Cochet M, Salloum M, Ikram S, Hayter E, Lim S, Hall T, Athaide S, Cosgrove CA, Tregoning JS, Le Doare K. Group B Streptococcus (GBS) colonization is dynamic over time, whilst GBS capsular polysaccharides-specific antibody remains stable. Clin Exp Immunol. 2022 Aug 19;209(2):188-200. doi: 10.1093/cei/uxac066.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019.0062
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.